CARA THERAPEUTICS
Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
CARA THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2004-07-02
Address:
Shelton, Connecticut, United States
Country:
United States
Website Url:
http://www.caratherapeutics.com
Total Employee:
101+
Status:
Active
Contact:
+1 203 567 1503
Email Addresses:
[email protected]
Total Funding:
472.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Devon Park BioVentures
Devon Park BioVentures investment in Series D - Cara Therapeutics
Mitsubishi Corporation
Mitsubishi Corporation investment in Series D - Cara Therapeutics
MVM Life Science Partners
MVM Life Science Partners investment in Series D - Cara Therapeutics
Connecticut Innovations
Connecticut Innovations investment in Series D - Cara Therapeutics
Scottish Widows Investment Partnership
Scottish Widows Investment Partnership investment in Series D - Cara Therapeutics
Ascent Biomedical Ventures
Ascent Biomedical Ventures investment in Series D - Cara Therapeutics
Alta Partners
Alta Partners investment in Series D - Cara Therapeutics
Rho Capital Partners
Rho Capital Partners investment in Series D - Cara Therapeutics
Connecticut Innovations
Connecticut Innovations investment in Series C - Cara Therapeutics
Devon Park BioVentures
Devon Park BioVentures investment in Series C - Cara Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-03 | Cara Therapeutics Announces CEO Transition |
Official Site Inspections
http://www.caratherapeutics.com Semrush global rank: 4.84 M Semrush visits lastest month: 1.85 K
- Host name: 196.133.155.104.bc.googleusercontent.com
- IP address: 104.155.133.196
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Cara Therapeutics"
Company - Cara Therapeutics
Our corporate strategy is to leverage our first-in-class lead product, difelikefalin, to potentially treat pruritus across various diseases. Our strategic priority is to develop and maximize the commercial potential of difelikefalin across multiple …See details»
Cara Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1 203 567 1503 Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and …See details»
Cara Therapeutics, Inc. (CARA) Company Profile & Facts - Yahoo …
See the company profile for Cara Therapeutics, Inc. (CARA) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Cara Therapeutics Company Profile | Management and Employees …
Www.caratherapeutics.com Cara Therapeutics Profile and History Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical …See details»
Cara Therapeutics - LinkedIn
Ir.caratherapeutics.com 20 Like Comment Share Cara Therapeutics 6,130 followers 8mo Report this post Don’t miss our virtual key opinion leader event, Meet the NP Experts, on Wednesday, …See details»
Cara Therapeutics - Overview, News & Similar companies
May 16, 2024 Cara Therapeutics contact info: Phone number: (203) 406-3700 Website: www.caratherapeutics.com What does Cara Therapeutics do? Cara Therapeutics is a clinical …See details»
Responsibility - Cara Therapeutics
Our dedication to patients goes hand in hand with our commitment to our ESG program. Building strong ESG practices and oversight into our scientific and business activities creates a culture of integrity at every level of the …See details»
News Release Details - Cara Therapeutics
Jan 22, 2024 “On behalf of the entire Cara team, I would like to express our sincere gratitude to Fred for all her contributions and dedication to the organization over the past 20 years. As one …See details»
Cara Therapeutics and Tvardi Therapeutics Announce Entry into …
4 days ago Management and Organization. Following the Merger, the combined company will be headquartered in Houston, Texas, and will be led by Tvardi’s CEO, Imran Alibhai, Ph.D., and …See details»
Cara Therapeutics - Craft
Cara Therapeutics has 5 employees at their 1 location and $20.97 m in annual revenue in FY 2023. See insights on Cara Therapeutics including office locations, competitors, revenue, …See details»
Cara Therapeutics, Inc. (CARA) Stock Price, Quote & News - Stock …
4 days ago Website https://www.caratherapeutics.com. Full Company Profile. Financial Performance. In 2023, Cara Therapeutics's revenue was $20.97 million, a decrease of …See details»
Cara Therapeutics, Inc. - BioCT
Cara Therapeutics is a clinical stage biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical …See details»
Cara Therapeutics and Tvardi Therapeutics Announce Entry into …
4 days ago Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi …See details»
Cara Therapeutics CEO and Key Executive Team | Craft.co
Cara Therapeutics's Chairman is Martin Vogelbaum. Other executives include Ryan Maynard, Chief Financial Officer; Jeffrey L. Ives, Director and 9 others. See the full leadership team at …See details»
Cara Therapeutics - VentureRadar
Similar Companies: Trevi Therapeutics USA Publicly Traded Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of …See details»
CARA Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
A replay of the webcast is available under “Events & Presentations” in the Investors section of the Company’s website, www.CaraTherapeutics.com. 1Q24 KORSUVA Injection U.S. Update In …See details»
Cara Therapeutics - Golden
Cara Therapeutics is a publicly held biotechnology company based in Stamford, Connecticut that was founded in 2004 by Derek Chalmers, Frederique Menzaghi, and Michael E. Lewis.It is …See details»
Cara Therapeutics Information - RocketReach
Caratherapeutics.com; boehringer-ingelheim.com; 3 203227XXXX; 203406XXXX; 203247XXXX; View Similar People. Related Companies Abyrx. 18 $5.2m Stamford Ophthalmology. 18 $5m …See details»
Innovation - Cara Therapeutics
Cara Therapeutics is a close-knit group of scientists, medical experts, and industry leaders deeply committed to the science of changing lives.See details»
Working At Cara Therapeutics: Company Overview and Culture
Www.caratherapeutics.com. Organization Type. Public. Social Media. Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human …See details»